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B
rain tumors are the second most frequently occurring neoplasms of childhood (Cohen and Duffner, 1994) and are associated with high rates of morbidity and mortality. Current treatment approaches using combinations of surgical resection, chemotherapy, and radiotherapy not only fail to effect a cure in many cases, but also are themselves associated with short-and longterm adverse effects. Thus, innovative approaches to therapy that reduce morbidity and improve survival are desperately needed.
CD95/Fas/APO-1/TNFRSF6 is a 45-kDa type I integral membrane protein belonging to the tumor necrosis/nerve growth factor superfamily of receptors (Itoh et al., 1991; Oehm et al., 1992) . The physiologic ligand of the Fas receptor, FasL, is a type II integral membrane protein homologous to TNF-a 3 (Kayagaki et al., 1997; Suda et al., 1993) , which may also be released from the cell surface as a functional, soluble 26-kDa molecule (Kayagaki et al., 1995; Tanaka et al., 1995) . Fas belongs to an emerging subfamily of TNF receptors, including TNF-R1, TRAIL-R1, TRAIL-R2, and APO-3 (Armitage, 1994) , that are characterized by the presence of a death domain within the cytoplasmic region (Itoh et al., 1993) . Multimerization of Fas receptors by FasL or agonistic antibodies leads to aggregation of the intracellular death domains (Boldin et al., 1995) . Association of adapter proteins with the death domains (Kischkel et al., 1995) initiates an intracellular proteolytic cascade involving caspases (Boldin et al., 1996; Medema et al., 1997; Muzio et al., 1996; Scaf di et al., 1998 ) that culminates in cleavage of cellular substrates and apoptosis in sensitive cells (Trauth et al., 1989; Yonehara et al., 1989) .
Fas-FasL interactions play important roles in elimination of autoreactive immune cells (Davidson et al., 1998; Watanabe-Fukunaga et al., 1992) , activationinduced T-cell death (Singer et al., 1994) , and killing by cytotoxic T lymphocytes (Hanabuchi et al., 1994) and natural killer cells (Oshimi et al., 1996) . FasL has been implicated in maintaining immune privilege in the anterior chamber of the eye (Grif th et al., 1995 (Grif th et al., , 1996 , in the mouse testis (Bellgrau et al., 1995; Duke et al., 1996; Yagita et al., 1996) , and in the brain . FasL is believed to deliver a death signal to the Fasexpressing immune cells in ltrating these tissues, resulting in suppression of immune activation.
Expression of Fas has been identi ed in glioma (Weller et al., 1994) and medulloblastoma cell lines (Weller et al., 1998) and in ex vivo astrocytic tumor specimens Tohma et al., 1998; Tachibana et al., 1995) . Expression of Fas mRNA in astrocytomas in vivo tends to correlate with a high degree of malignancy (World Health Organization grades III and IV; Tachibana et al., 1995) . However, the Fas protein appears to be predominantly expressed in association with large areas of necrosis within tumor tissue . Furthermore, both human glioma cell lines (Weller et al., 1994 (Weller et al., , 1995a (Weller et al., , 1995b and ex vivo glioma cells have been shown to be susceptible to apoptosis induced by FasL or anti-Fas antibodies. Preexposure of cell lines to various cytokines, including TNF-a and interferon-g (Weller et al., 1994) , and increased production of endogenous TGF-b1 by glioma cells (Ashley et al., 1998) were shown to enhance Fas cytotoxicity. This, and the absence of Fas on normal brain parenchyma (Leithauser et al., 1993) , led to interest in Fas as the target of a novel immunotherapeutic approach against these tumors.
Malignant gliomas are among a number of solid tumors, including colon carcinoma (O'Connell et al., 1996) , hepatocellular carcinoma (Strand et al., 1996) , esophageal carcinoma , and melanoma (Hahne et al., 1996) , that express FasL Weller et al., 1998) . Membrane-bound FasL on cell lines (Hahne et al., 1996; Strand et al., 1996) or ex vivo cells O'Connell et al., 1996; Walker et al., 1997) is capable of inducing cell death in Fas-sensitive target cells. This is believed to represent a mechanism by which tumors can counterattack tumor-in ltrating lymphocytes and cytotoxic T cells and thereby escape immune surveillance (O' Connell et al., 1996) .
It is not known whether the previously published ndings from adult malignant glioma can be generalized to include other tumors of the CNS, including pediatric malignancies. In this report, Fas expression was identied in all of the pediatric brain tumors tested. FasL was coexpressed in 9 of the 13 tumors tested by both Western blot and immunohistochemistry. Despite the presence of the receptor on tumor cells, a large degree of resistance to Fas-mediated apoptosis was observed in all the tumor specimens.
Methods

Cell Lines
Neuro-2A murine neuroblastoma cell lines were provided by Dr. Adriano Fontana (University Hospital, Zurich, Switzerland). Neuro-2A/FasL cells have been engineered to produce soluble FasL by stable transfection with the BCMGS expression plasmid, subcloned with cDNA encoding murine FasL (Rensing-Ehl et al., 1995) . Murine and human FasL share 76.9% homology at an amino acid level and are functionally interchangeable (Nagata and Golstein, 1995) . Neuro-2A/neo cells transfected with an empty BCMGS vector served as a control in experiments using the FasL-containing supernatant uid. Cell lines were maintained in zinc option medium (GIBCO BRL, Grand Island, N.Y.) supplemented with 10% heat-inactivated fetal calf serum (Trace Biosciences, Castle Hill, New South Wales, Victoria, Australia).
Dissociation of Brain Tumor Specimens
Primary pediatric tumor specimens that were surplus to pathology were collected during surgical procedures at the Royal Children's Hospital, Melbourne, Victoria, Australia, after Ethics in Human Research Committee approval. Due to ethical and logistical considerations, it was not always possible to obtain a truly representative sample of the tumor. If immediate processing of tumor specimens was not feasible, specimens were stored at 4°C for less than 12 h. Tumor samples were maintained in zinc option medium/10% fetal calf serum, mechanically dissociated, and then triturated by passage through 18-to-25-gauge needles. Any solid debris preventing passage of the cell suspension was removed and discarded. Successful passage through a 25-gauge needle indicated a single cell suspension had been obtained, as con rmed by microscopic examination. Red blood cells were lysed by incubation in ammonium chloride solution (0.15M NH 4 Cl, 20 mM Tris, pH 7.4) for 2 min at room temperature, and tumor cells were resuspended in culture medium. After assessment of viable cell number by trypan blue exclusion (Sigma, St Louis, Mo.), the tumor suspension was diluted to obtain a nal concentration of 10 6 viable cells/ml.
Labeling Cells for Immunophenotyping
FACS analysis was performed on freshly obtained tumor cell suspensions. Cells (10 6 ) were centrifuged (500g, 5 min, 4°C), washed in FACS buffer (1% bovine serum albumin, 0.05% NaN 3 , in PBS, pH 7.4), and incubated with an anti-Fas monoclonal antibody (DX2, mouse IgG 1 ; PharMingen, San Diego, Calif.; 1 mg/ml) or an isotype control antibody for 30 min, on ice. The cells were washed with FACS buffer and incubated with a uores-cein isothiocyanate-conjugated, af nity-isolated, sheep anti-mouse secondary antibody [F(ab) 2 fragment], (Amrad Pharmacia, Melbourne, Victoria, Australia; diluted 1:40). After incubation on ice for 30 min, the cells were washed in FACS buffer, resuspended in 200 ml FACS xative (0.9% NaCl, 2% glucose, 2% formaldehyde), and incubated at 4°C until analyzed. Reference cells were kept unstained after the rst wash and resuspended in FACS xative. The Jurkat cell line served as a positive control for each experiment and, where the volume of tumor suspension allowed, the experiment was conducted in duplicate.
FACS Analysis of Tumor Specimens
A total of 10,000 events were collected on the FACScan (Becton Dickinson Immunocytometry Systems, San Jose, Calif.) using CYCLOPS TM software (Cytomation Inc., Fort Collins, Colo.). The laser was tuned at 488 nm with an output power of 15 mW. Fluorescein isothiocyanate-emitted "green" uorescence was collected via a DM560-nm/22.5°dichroic mirror (>560-nm re ection) and a DF530/30-nm band pass lter. Cellular debris was excluded from the analysis.
The MFR was calculated as the ratio of the mean uorescence of DX2 (anti-Fas)-labeled cells and that of cells labeled with the isotype control antibody.
To quantitate the percentage of tumor cells that were positive for Fas expression, we used WinMDI Version 2.7 software (Scripps Research Institute, La Jolla, Calif.) to directly compare the uorescence pro le of DX2-stained cells with the pro le of cells stained with the isotype control. The DX2-and isotype-stained cell pro les were overlaid on the same histogram. A marker was set, de ned at its lower limit by the point of intersection of the 2 pro les. The percentage of cells considered positive for Fas was calculated by subtracting the percentage of isotype-labeled cells from the percentage of DX2-labeled cells uorescing within the region de ned by the marker.
Western Blotting
Thirteen frozen tumor samples were selected according to availability of tumor tissue and coarsely chopped before suspension in 5 volumes (wt/vol) RIPA buffer (1% sodium dodecyl sulfate, 1% NP40 in PBS, pH 7.4) with protease inhibitor cocktail set 1 (Calbiochem, La Jolla, Calif.). Tumor samples were homogenized using a Polytron homogenizer and boiled in sample buffer before separating the proteins on 10% sodium dodecyl sulfate-polyacrylamide gels and transferring them to Hybond TM -P membranes (Amersham Pharmacia Biotech, Buckinghamshire, U.K.). Supernatant uid from Neuro-2A/FasL-expressing cells was used as a positive control for FasL expression. Membranes were blocked for 1 h at room temperature in 5% nonfat milk/TBST (0.1% Tween 20, 125 mM NaCl, and 25 mM Tris, pH 7.4). Blots were then probed overnight at 4°C with rabbit polyclonal anti-human FasL antibody (Q20; Santa Cruz Biotechnology, Santa Cruz, Calif.; 1:100) or anti-b2-microtubulin (PharMingen; 1:100) as a loading control. Q20 anti-FasL antibody was selected because of its minimal cross-reactivity when compared with NOK-1 and G247-4 (both PharMingen). Blots were then incubated with horseradish peroxidase-conjugated secondary antibodies (1:100,000) followed by enhanced chemiluminescence detection with Supersignal ® West Pico Chemiluminescent Substrate, according to the manufacturer's instructions (Pierce, Rockford, Ill.). The blots were exposed to Kodak XR lm (Eastman Kodak, Rochester, N.Y.) for 2 s to 20 min.
Immunohistochemical Detection of Fas and FasL
Formalin-xed, paraf n-embedded blocks of each tumor were obtained from the Department of Anatomical Pathology, Royal Children's Hospital, Melbourne, Victoria, Australia. Sections, 4-mm thick, were cut and placed on poly-L-lysine-coated slides (Sigma). The sections were deparaffinized in xylene and rehydrated. Antigen retrieval was performed by immersing the slides for 30 min in 0.01 M sodium citrate buffer preheated to 95°C (Kawai et al., 1994; Werner et al., 1996) . Endogenous peroxidase activity was quenched by incubating the sections in 1% hydrogen peroxide for 20 min. A blocking step was performed for 2 h at room temperature with PBS containing 5% normal goat serum (Vector Laboratories Inc., Burlingame, Calif.) and 10% normal human serum. Sections were incubated overnight at 4°C with rabbit polyclonal anti-human FasL antibody (Q20; Santa Cruz Biotechnology; 1:100) or anti-human Fas antibody (Ab-1, Calbiochem; 1:40). After 3 washes in PBS, the sections were incubated with biotin-conjugated goat antirabbit antibody (PharMingen; 1:200) for 30 min at room temperature. The reaction was visualized using the Vectastain Elite ABC kit (Vector Laboratories, Inc.) and a 3,39 -diaminobenzidine substrate (Sigma). The slides were counterstained in hematoxylin (Shandon Southern Products Ltd., RuncornCheshire, U.K.). Formalin-fixed, paraf n-embedded sections of human liver and mouse spleen served as positive controls for Fas and FasL, respectively. Negative controls consisted of sections without primary or secondary antibody and those incubated with nonimmunized rabbit serum. Antibodies and control rabbit serum were diluted in 1% normal goat serum in PBS. Representative sections on which immunohistochemistry was not performed were stained with hematoxylin and eosin (Shandon Southern Products, Ltd.) for identi cation and classi cation of the tumor.
The level of Fas and FasL expression was determined by assessment of the percentage of immunoreactive cells in 10 nonadjacent high-powered elds (original magni catioń 400). The average of the 10 elds was calculated and recorded as either no expression, <5% cells positive, 5% to 25% cells positive, 25% to 50% cells positive, or >50% cells positive. The staining intensity of tumor cells was rated as weak, moderate, or intense.
The cell-free supernatant uid was then used at the dilutions speci ed or stored at -20°C until used.
Flow Cytometric Determination of Cell Viability by FACS Analysis
In a 12-well plate, 1 ml tumor cells at a viable cell concentration of 10 6 /ml was incubated in triplicate with each medium alone, etoposide (10 mg/ml), and APO-1 antibody (100 ng/ml) with protein A (1:10,000) for 24 h (37°C, 5% CO 2 , 96% humidity). For specimens PN2 and MB1, the combination of APO-1 and protein A was replaced with Neuro-2A/FasL supernatant uid diluted 1:2, and cells exposed to an equivalent dilution of Neuro-2A/neo supernatant uid served as a negative control. Wells containing Jurkat cells at 10 6 /ml served as positive controls for each condition.
At 24 h, all cells were harvested from each well by vigorous pipetting. Adherent cells were removed by incubating with trypsin-EDTA. Each well was washed 3 times with PBS, and lack of residual cells was con rmed by microscopic examination. The cells were centrifuged (500g, 5 min, 4°C), resuspended in 300 mL FACS buffer containing 50 mg/ml propidium iodide (Sigma), and incubated on ice for 1 h.
Sub G 1 Peak Analysis of Apoptotic Cell Death
After assessing viability by ow cytometry, we xed the cells for sub G 1 peak analysis (Tounekti et al., 1995) by adding 250 ml of 70% ethanol to achieve a nal concentration of approximately 35%. After overnight incubation at 4°C, samples were centrifuged (500g, 5 min, 4°C) and resuspended in 200 ml propidium iodide at 50 mg/ml in PBS.
Between 10,000 and 20,000 events were collected for analysis on the FACScan using settings described for analysis of viability. Of the events remaining after doublet discrimination, cells uorescing below 25% of the G 1 peak uorescence were assumed to be debris and were excluded from analysis. Cells uorescing above this limit, but below the intensity of the G 1 peak, were designated apoptotic, and the percentage of total tumor cells they represented was calculated.
Colorimetric Assay for Determining Total Viable Cell Number
Cell viability across a 48-h period was measured using the CellTiter 96 ® AQ ueous Non-Radioactive Cell Proliferation Assay (Promega, Madison, Wisc.), which detects mitochondrial activity, according to the recommended protocol. In a 96-well plate, 50 ml tumor cell suspension at 4 ´10 5 /ml was incubated with etoposide (10 mg/ml), or anti-Fas antibody APO-1 (100 ng/ml) with protein A (1:10,000), or in the absence of inducers of apoptosis, in a nal volume of 100 ml. In later experiments (specimens MB1 and PN2), the combination of APO-1 and protein A was replaced with Neuro-2A/FasL supernatant uid diluted 1:2, with parallel wells containing Neuro-2A/neo supernatant uid diluted 1:2 serving as a negative control. The experiment was conducted in triplicate and incubated over a 48-h period (37°C, 5% CO 2 , 96% humidity). Jurkat cells at a nal concentration of 2 1 0 5 /ml were used as a positive control for each treatment. Wells containing 100 ml medium and substrate provided a measurement of the background reading at 490 nm resulting from absorbance within the medium at this wavelength.
Substrate (20 ml/well) was added at 0-, 24-, and 48-h time points after the assay was established, and after a further 3-h incubation, the absorbance at 490 nm was measured with an ELISA plate reader (reference wavelength, 620 nm). Absorbance readings were adjusted to remove the contribution of background absorbance, and viability was calculated at each time point as a percentage of the average absorbance from wells containing no apoptosis inducers at the same time point.
Statistical Analysis
We determined the signi cant differences between treatments in individual tumor specimens by using Student's t test (Altman, 1991) . We compared the overall difference in viability in the anti-Fas treatment and control groups in the medulloblastoma/PNET specimens using two-way ANOVA on Stata Corporation 1997 (Stata Statistical Software, Release 5.0, College Station, Tex.).
Results
Tumor Samples
The 18 pediatric brain tumor specimens analyzed for expression of Fas and FasL are described in Table 1 according to histology, patient age, and sex. The specimens consisted of 9 PNETs that included 6 medulloblastomas, 4 glioblastomas multiforme, 3 low-grade gliomas, a ganglioglioma, and a germ-cell tumor.
Fas Expression
Immunohistochemistry. Giemsa staining of tumor sections revealed morphologic differences between tumor cells as well as necrotic and apoptotic tissue. Small numbers of normal brain cells, epidermal cells, and blood cells were also present in the samples. Immunohistochemically, the Fas receptor was detected in all 18 tumor specimens ( Table 2 ). The cytoplasm and membrane of positive tumor cells stained diffusely. Walls of blood vessels, red blood cells, large areas of necrotic tissue, and areas of desmoplasia were negative, and staining was consistently absent in negative controls without primary or secondary antibody.
Tumor sections with little variation in cellular morphology demonstrated uniform intensity of Fas staining throughout. In perinecrotic areas of tumor tissue, an apparent increase in the number and staining intensity of Fas-positive tumor cells was frequently observed. Tumors were rated according to the percentage of tumor cells expressing the Fas receptor and the staining intensity of these cells (Table 2) .
PNET/medulloblastoma. Weakly Fas-positive cells were found to constitute 25% to 50% of cells in 4 of the 9 PNET/medulloblastoma specimens and more than 50% of cells in another 4 tumors of this group. In the remaining medulloblastoma, only occasional cells appeared immunoreactive to Fas. Two tumors, PN1 and MB2, otherwise demonstrating relatively consistent staining for Fas, contained populations of apoptotic cells with hyperchromatic, condensed nuclei that did not express Fas. PN2 contained a large cell population suggestive of gliomatous differentiation that expressed Fas more consistently and prominently than did small cells within the tumor. Against a weak background of faintly staining tumor cells, MB3 demonstrated intense staining on large cells with prominent nuclei. Occasional Fas-positive Purkinje cells were seen within the tumor tissue.
Glioblastoma. Of the 4 glioblastomas, GBM1 (Fig. 1 ) and GBM4 demonstrated relatively intense staining for Fas on more than 50% of cells, and GBM2 and GBM3 demonstrated more moderate staining on 25% to 50% of cells. Neurons in the tissue surrounding GBM3 also appeared positive for Fas expression.
Flow cytometry. Fas expression was assessed by ow cytometric analysis. Fluorescence pro les were used to calculate the MFR and the percentage of cells expressing Fas (Fig. 2) . The well-characterized Jurkat lymphoma cell line was included as a positive control for constitutive receptor expression. Almost all Jurkat cells were found to (Table 2 ). There was a relationship between the percentage of Fas-positive cells and MFR (r = 0.84). However, no real difference was observed between tumor subtypes (data not shown). The variation in Fas expression in individual tumor specimens was generally greater than that in the Jurkat population. This was exempli ed by the pro les of two specimens, GBM1 (Fig. 1) and GBM3, which demonstrated small proportions of cells uorescing at levels 1 or 2 log higher than the peak uorescence of the population. The level of Fas expression, as measured both by the percentage of Fas-positive cells (42.1 ± 18.1) and the MFR (2.37 ± 0.70) in tumor samples, was considerably less than that observed in the Jurkat cells. There was a poor correlation between surface Fas expression measured by ow cytometry and immunohistochemical positivity, suggesting that in some tumors, a large proportion of Fas may be intracellular.
FasL Expression
Immunohistochemistry. Immunohistochemically, FasL was detected in 17 of the 18 tumors (Table 3 ). There tended to be more homogeneity, both across tumor subtypes and within each individual tumor, than for Fas expression.
PNET/medulloblastoma specimens all demonstrated expression of FasL on more than 50% of tumor cells at various staining intensities. Apoptotic cells in PNET/medulloblastoma specimens that did not express Fas were similarly not immunoreactive for FasL.
Western blotting. Western blotting detected FasL in 10 of the 13 tumors examined (Table 3) . Of the 7 PNET/medulloblastomas examined, 5 were positive for FasL expression. Staining intensity of positive specimens was compared with reference to the b-tubulin loading control (Fig. 3) . Intensity ranged from very weak (MB4) to strong (MB5 and MB6), with MB1 and MB2 being intermediate. PNET 2 and PNET3 specimens were negative for FasL expression. Of the glioblastomas, all expressed FasL, with GBM4 having the highest level of expression of all the tumors tested. However, GBM1 and GBM3 showed relatively low levels of expression. Of the low-grade tumors, LGG4 showed a low expression level, with the other two having no, or barely detectable, FasL expression. Many cross-reactive high-molecular-weight bands were seen in most tumor samples, and this may account for the poor correlation between the Western blot and immunohistochemical results.
Sensitivity of tumor specimens to Fas-mediated apoptosis. Cell viability was measured by ow cytometry at 24 h and by a colorimetric assay for total viable cell number at 24-and 48-h time points. Additionally, sub G 1 peak analysis of cells cultured for 24 h in the presence or absence of apoptotic mediators provided a measure of the percentage of apoptotic cells present in each specimen. Cell viability/apoptosis in the presence of etoposide or anti-Fas treatment was expressed as a percentage relative to the number of viable/apoptotic cells in the absence of any treatment at the same time point.
Cell death assays were rst established using the ing FasL at equivalent dilutions had no effect on viability compared with cells cultured in medium alone.
Speci city of killing was con rmed by demonstrating that the cytotoxicity of Neuro-2A/FasL supernatant uid could be abrogated by the addition of a monoclonal antiFas antibody (DX2) that competitively inhibits binding of FasL to its receptor (data not shown) (Huang et al., 1999) . The cell death rate in Jurkat with APO-1/protein A was the same as with the highly apoptotic Neuro-2A/FasL supernatant uid. However, the death rate in cells assayed with APO-1 antibody alone was far lower. After this observation, Jurkat was used as a positive control in comparing Neuro-2A/FasL supernatant uid to APO-1/protein A in MB1. Again, both Neuro-2A/FasL supernatant uid and APO-1/protein A were highly apoptotic in the Jurkat cell line and showed the same degree of cell death in the tumor sample, indicating that Neuro-2A/FasL supernatant uid and APO-1/protein A are equivalent in these assays. Therefore, PNET2 was assayed using Neuro-2A/FasL supernatant uid only, again with Jurkat as a control.
The reference Jurkat cell line also showed a dramatic decrease in the percentage of viable cells in the presence of the topoisomerase II inhibitor, etoposide. The corresponding increase in the percentage of apoptotic cell numbers con rmed the loss of viability was due to induction of apoptosis by this agent.
Of the 18 tumor specimens, 9 were analyzed for sensitivity to Fas-mediated and drug-induced apoptosis, including 4 PNETs (2 medulloblastomas), 3 glioblastomas, and 2 low-grade gliomas. These tumors were selected according to the availability of tumor tissue. In all 9 tumor specimens, spontaneous cell death occurred, and a decrease in the number of viable cells was observed over 48 h of culturing in medium without the addition of etoposide or anti-Fas antibody/protein A. In most tumors (7 of 9), the loss of viable cell number was less than 50% (data not shown) when compared with the viability at the initial analysis.
The measures of viability at 24-h ow cytometry and colorimetric viability assay were comparable. Tumors resistant to either anti-Fas treatment or etoposide at the 24-h time point were similarly resistant at 48 h. In tumor samples sensitive to these agents at 24 h, the effect became more pronounced at the 48-h time point of the colorimetric viability assay. Of the 9 tumors, 4 were sensitive to apoptosis mediated by either etoposide or the Fas receptor (Table 4) . Patient specimen MB1 was treated with both APO-1/protein A and Neuro2A/FasL supernatant to assess the sensitivity of the tumor to Fas-mediated apoptosis. Although the viability of MB1 decreased over 48 h after exposure to etoposide at 10 µg/ml, the tumor was resistant to both forms of anti-Fas treatment (data not shown). PN2 was treated with Neuro2A supernatant uid only, and the remaining tumors were treated with APO-1/protein A only.
Of the 4 PNET specimens, 2-MB1 and PN2-were sensitive to induction of apoptosis by etoposide (Table 4) . Corresponding increases in apoptotic cell numbers, compared with cells cultured in medium only, were observed at 24 h by sub G 1 peak analysis (Table 5 ). The maximum decrease in viability detected at 48 h by the colorimetric viability assay was 15.6%. Some sensitivity to Fas-mediated apoptosis was demonstrated in 2 of the 4 PNET specimens, PN2 and MB3. The maximum decrease in the percentage viability observed after 48 h, compared with cells cultured in medium alone, was 41.9%. Only 1 PNET specimen, PN2, was sensitive to induction of apoptosis by both etoposide and the Fas pathway. PN1 was resistant to both treatments.
All four medulloblastoma/PNET specimens demonstrated a decrease in viability at 48 h after anti-Fas treatment compared with control cells cultured in medium alone. However, the decrease in viability in each individual specimen was generally small and did not reach statistical signi cance in triplicate cultures of 2 of the 4 specimens, due to intra-assay variability. Two-way ANOVA analysis of this tumor family, taking into account differences in the average viability of the individual specimens, suggests the overall viability of the anti-Fas treatment group is less than that of the control group at 48 h (P = 0.0004).
Sensitivity to Fas-mediated apoptosis was demonstrated in one of the glioblastoma specimens, GBM1, whereas none of the glioblastomas were killed by etoposide (Table 4) . Both low-grade glioma specimens were resistant to apoptosis mediated by both Fas and etoposide.
In the 3 brain tumor specimens sensitive to Fas-mediated apoptosis, viability decreased to only 81.7 ± 10.8% (mean ± SD of combined data from ow and colorimetric viability assay) after 24 h. At 48 h, the decrease in the percentage of viable cells was more pronounced (66.6 ± 9.92%). The rates of killing were signi cantly less than those observed in the Jurkat cell line. Overall, there was a general resistance to apoptosis mediated by either the Fas pathway or the chemotherapeutic drug etoposide in the pediatric brain tumors analyzed, with 5 of 9 brain tumors not responding to either treatment.
Discussion
Fas/APO-1/CD95/TNFRSF6 is a member of the tumor necrosis factor/nerve growth factor receptor family that induces a death signal in sensitive cells after multimerization by its natural ligand or agonistic antibodies. Exploitation of the Fas apoptotic pathway as a novel immunotherapeutic approach against gliomas was given impetus by the demonstration that Fas is expressed on malignant glioma cells both in vitro (Weller et al., 1994) and ex vivo Tachibana et al., 1995; Tohma et al., 1998) , that glioma cells are susceptible to Fas-induced apoptosis (Weller et al., 1994 (Weller et al., , 1995a (Weller et al., , 1995b , and that Fas is absent from normal brain parenchyma (Leithauser et al., 1993) . Sensitivity to Fas in ex vivo glioma specimens has recently been reported . It has also been shown that some medulloblastoma cell lines show a low level of Fas expression, coexpression of FasL, and sensitivity to FasL-mediated apoptosis. However, to date there has been no study of ex vivo tissue from pediatric brain tumors or brain tumors other than adult gliomas (Weller et al., 1998) . It is important to study Fas expression and activity in freshly resected primary tumor specimens because, due to the selection pressures of culture conditions, the in vitro phenotype of tumor cells may not re ect the in vivo situation (Izumu et al., 1993) . The ex vivo tumors analyzed in this study consisted of various subtypes, including 9 PNET/medulloblastomas, 4 glioblastomas multiforme, 4 low-grade gliomas, and a germ-cell tumor of the CNS.
The Fas receptor was detected by ow cytometry in all 18 brain tumors. Compared with the Jurkat cell line, a moderate level of Fas expression was detected in primary pediatric tumors of the CNS. There was signi cant heterogeneity in Fas expression within each tumor subtype and no obvious correlation with grades of malignancy, as previously reported for expression of Fas mRNA in adult malignant gliomas (Tachibana et al., 1995) .
Expression of Fas on tumor cells in each of the 18 specimens was confirmed by immunohistochemical analysis. As observed by ow cytometric immunophenotyping, expression of the Fas receptor again appeared quite heterogeneous both in individual tumor sections and within tumor subtypes. In concert with previous reports , there was an apparent increase in the frequency and intensity of Fas immunoreactivity in perinecrotic areas of several sections.
Of interest in this study was the observation in PNET/medulloblastoma specimens (PN1, MB2) of Fasnegative or weakly staining apoptotic cells among otherwise homogenous populations of tumor cells expressing rons in the cerebellar and cerebral cortices (Leithauser et al., 1993) . However, exposure to interferon-g has been shown to induce low levels of Fas expression on neurons without resulting in sensitivity to Fas-mediated apoptosis (Rensing-Ehl et al., 1996) . Thus, Fas expression observed on neurons in this study may be a consequence of the environment in and around the tumor tissue. The susceptibility of Fas-expressing neurons to Fas-mediated apoptosis was not explored, and indeed receptor expression may not necessarily correlate with Fas-sensitivity. Of the two specimens containing Fas-expressing neurons, GBM3 demonstrated no decrease in viable cell number after anti-Fas treatment, whereas a slight decrease was observed in MB3. The lack of sensitivity of GBM3 may suggest that these neurons, like the tumor cells, are resistant to Fas-mediated apoptosis. Of the 9 pediatric brain tumors analyzed in cytotoxicity assays, 6 were resistant to Fas-induced apoptosis despite the expression of Fas on tumor cells. Seven were resistant to apoptosis induced by the topoisomerase II inhibitor etoposide. Analysis of the overall viability of the medulloblastoma/PNET tumors as a group demonstrated a reduced viability of tumor cells 48 h after exposure to anti-Fas treatment compared with exposure to medium alone. This observation suggests that this subgroup of embryonal tumors appears to exhibit an overall sensitivity to Fas not observed in the astrocytic pediatric tumors included in this study. Furthermore, the glioblastoma, GBM1, that appeared sensitive to Fas-induced apoptosis was derived from an infant.
One glioblastoma and 2 PNETs demonstrated sensitivity to Fas-mediated apoptosis. The loss of viability in these specimens was signi cantly less pronounced than that observed in the Jurkat cell line after 48 h. The difference in effect may be due in part to the presence of proliferating Fas-negative cells in short-term cultures of primary tumor specimens. At each time point, viability in the presence of either treatment was expressed relative to the number of viable cells in control samples that had been cultured in medium alone. Jurkat controls cultured in medium over a 48-h period were observed to proliferate, with absorbance readings in the colorimetric viability assay tripling over the time period (data not shown). The equivalent tumor controls demonstrated a decrease in viability over time. Thus, for an equivalent decrease in viable cell number, the percentage viability calculated would be relatively larger in tumor specimens compared with the Jurkat cell line. Nonetheless, the dramatic loss of Jurkat cell viability demonstrated by forward scatter/side scatter analysis and propidium iodide exclusion was not observed in tumor specimens.
Fas sensitivity among the tumor specimens did not correlate with the level of Fas expression. For instance, patient specimen PN2 was susceptible to Fas-mediated apoptosis yet demonstrated a lower percentage of Faspositive cells and a lower MFR than MB1, which was resistant to Fas-induced apoptosis.
The degree of Fas-resistance observed in this study contrasts with previous ndings , which demonstrated sensitivity to the highly apoptotic Neuro-2A/FasL supernatant uid (Schneider et al., 1998) . Although APO-1 in combination with protein A gave equivalent results to the FasL-transfected Neuro-2A supernatant uid in Jurkat and MB1, the contrast in ndings may re ect differences between these two death-inducing agents. Alternatively, differences in the biology of pediatric compared with adult malignancies of the CNS, or variation between individual tumors, may contribute to the difference in results.
Failure of pediatric brain tumor specimens to undergo Fas-induced apoptosis, despite signi cant levels of Fas expression, suggests the existence of mechanisms of resistance affecting the ability of the receptor and/or the intracellular cascade to transduce the death signal. The corresponding lack of susceptibility to etoposide suggests the resistance observed is not speci c for the Fas pathway and may involve factors involved in multiple pathways of apoptosis.
The previously reported results in glioma specimens and the results of this study suggest expression of the Fas receptor and its ligand appear to be general characteristics of brain tumors. It remains to be shown that FasL expressed on pediatric brain tumors, like that on adult gliomas, is indeed capable of transducing an apoptotic signal to Fas-sensitive target cells and maintaining immune privilege in the tumor environment.
The function of Fas expression on brain tumor cells remains to be explained. It has been reported that Fas signaling induces the release of cytokines from astrocytes, which regulate the in ammatory response (Saas et al., 1999) . It is also likely that Fas signaling is associated with a proliferative effect in T cells . The coexpression of Fas and FasL in some pediatric brain tumors may help stimulate the proliferative or immunologic arms of the Fas pathway. FasL expression is perhaps easiest to explain in terms of its role in the down regulation of activated T cells. In this way, the transformed cells could modulate the immune response to a tumor. For tumor cells to express both Fas and FasL, the proapoptotic arm of the Fas signaling pathway is likely to be nonfunctional in these cells. This could occur through loss of function of elements in the apoptosis pathway or expression of active inhibitors of the pathway. The molecular environment within the tumor and the CNS may also alter the consequence of Fas signaling within the cell. Subversion of elements of the apoptosis pathway to a proliferation or survival pathway would provide not only a growth advantage but also could account for the resistance to apoptosis in these pediatric brain tumors.
The Fas receptor may represent an attractive target for an immunotherapeutic approach. However, despite demonstration of Fas-sensitivity in medulloblastoma/ PNET specimens, a high degree of resistance to Fasmediated apoptosis was observed in ex vivo pediatric brain tumors despite the presence of signi cant levels of receptor expression. This, as well as the presence of substantial subpopulations of Fas-negative tumor cells in most specimens, suggests that an immunotherapeutic approach targeting the Fas-receptor alone may be ineffective in signi cantly reducing the tumor load, and its potential, if any, may lie in combination with existing therapies.
